1-(1H-indazol-3-yl)propan-1-one | 36961-01-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-(1H-indazol-3-yl)propan-1-one
• 英文别名: 3-Propionylindazol；1-(1(2)H-indazol-3-yl)-propan-1-one
• CAS: 36961-01-0
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: OCHHFSFKIFAVNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对甲苯磺酰氯 、 1-(1H-indazol-3-yl)propan-1-one 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以90%的产率得到1-(1-tosyl-1H-indazol-3-yl)propan-1-one
  参考文献：
  名称：

  锌-乙酸促进α-氨基酮的还原碳-氮键断裂反应

  摘要：

  Scope and limitation of the reductive cleavage reaction of a-aminoketone systems with zinc-acetic acid are described. The carbon-nitrogen bond cleavage reaction was applicable to a wide range of alpha-aminoalkyl aryl ketones possessing various substituents on the aromatic ring. In contrast, a-aminoalkyl alkyl ketones with protons at the alpha'-position or alpha-aminoesters were sluggish to the carbon-nitrogen cleavage reaction.

  DOI：

  10.3987/com-13-s(s)64
• 作为产物：
  描述：

  1-(1-tosyl-1H-indazol-3-yl)propan-1-one 在 碘苯 、 溶剂黄146 、 间氯过氧苯甲酸 、 锌 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 25.0h， 生成 1-(1H-indazol-3-yl)propan-1-one
  参考文献：
  名称：

  锌-乙酸促进α-氨基酮的还原碳-氮键断裂反应

  摘要：

  Scope and limitation of the reductive cleavage reaction of a-aminoketone systems with zinc-acetic acid are described. The carbon-nitrogen bond cleavage reaction was applicable to a wide range of alpha-aminoalkyl aryl ketones possessing various substituents on the aromatic ring. In contrast, a-aminoalkyl alkyl ketones with protons at the alpha'-position or alpha-aminoesters were sluggish to the carbon-nitrogen cleavage reaction.

  DOI：

  10.3987/com-13-s(s)64

文献信息

• NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：EP4001279A1

  公开（公告）日：2022-05-25

  The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

  本发明公开了式（Ia）化合物及其药学上可接受的盐类： 其可抑制冠状病毒的复制活性。本发明进一步涉及包含式（Ia）化合物或其药学上可接受的盐的药物组合物，以及治疗或预防有需要的受试者冠状病毒感染的方法，包括向受试者施用治疗有效量的式（Ia）化合物或其药学上可接受的盐。
• Spiropyrrolidine derived antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11384090B2

  公开（公告）日：2022-07-12

  The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

  本发明公开了式（Ia）化合物及其药学上可接受的盐类： 其可抑制冠状病毒的复制活性。本发明进一步涉及包含式（Ia）化合物或其药学上可接受的盐的药物组合物，以及治疗或预防有需要的受试者感染冠状病毒的方法，包括向受试者施用治疗有效量的式（Ia）化合物或其药学上可接受的盐。
• [EN] THERAPEUTIC INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS THÉRAPEUTIQUES
  申请人：LIFESCI PHAMACEUTICALS INC

  公开号：WO2017098328A2

  公开（公告）日：2017-06-15

  Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds which are complement factor D inhibitors. Such compounds are useful for treating complement related disorders including, but are not limited to, autoimmune, inflammatory, and neurodegenerative diseases.